Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the ...
AOL

What Your PSA Test Says About Your Prostate

THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...